{
    "Trade/Device Name(s)": [
        "Wako LBA DCP",
        "Wako DCP Calibrator Set",
        "Wako DCP Control Set"
    ],
    "Submitter Information": "Wako Chemicals USA, Inc.",
    "510(k) Number": "K062368",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OAU",
        "JIT",
        "JJX"
    ],
    "Summary Letter Date": "December 14, 2006",
    "Summary Letter Received Date": "December 21, 2006",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.6030"
    ],
    "Regulation Name(s)": [
        "AFP-L3% Immunological Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "immunology",
        "coagulation"
    ],
    "Analyte(s)": [
        "Des-gamma-carboxy Prothrombin (DCP)"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LiBASys"
    ],
    "Method(s)/Technology(ies)": [
        "Immunochemical technique",
        "Liquid-phase Binding Assay (LBA)",
        "Fluorophotometric measurement",
        "Column chromatography"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control",
        "Reagent",
        "Automated instrument"
    ],
    "Document Summary": "FDA 510(k) summary for Wako LBA DCP immunological test system measuring DCP in serum to assess risk of hepatocellular carcinoma in chronic liver disease patients",
    "Indications for Use Summary": "Aids in risk assessment for progression to hepatocellular carcinoma in chronic liver disease patients by quantitative measurement of DCP in human serum, used with other laboratory, imaging, and clinical findings",
    "fda_folder": "Immunology"
}